The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L03 | Immunostimulants | |
3
|
L03A | Immunostimulants | |
4
|
L03AA | Colony stimulating factors |
| Code | Title | |
|---|---|---|
| L03AA02 | Filgrastim | |
| L03AA03 | Molgramostim | |
| L03AA09 | Sargramostim | |
| L03AA10 | Lenograstim | |
| L03AA12 | Ancestim | |
| L03AA13 | Pegfilgrastim | |
| L03AA14 | ||
| L03AA15 | ||
| L03AA18 | ||
| L03AA19 |
| Active Ingredient |
|---|
|
Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Efbemalenograstim alfa is a recombinant fusion protein containing G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2. Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. |
|
Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival. Eflapegrastim-xnst has been shown to elevate neutrophil counts in healthy subjects and in cancer patients. |
|
Filgrastim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes. |
|
Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration. |
|
Lipegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Lipegfilgrastim binds to human the G-CSF receptor like filgrastim and pegfilgrastim. Human G-CSF is a glycoprotein that regulates the production and release of functional neutrophils from the bone marrow. |
|
|
|
Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. |
|
Sargramostim is a recombinant human GM-CSF. The binding to GM-CSF receptors expressed on the surface of target cells (haematopoietic progenitors and mature immune cells), initiates an intracellular signalling cascade which induces the cellular responses (i.e., division, maturation, activation). GM-CSF is a multilineage factor and, in addition to dose-dependent effects on the myelomonocytic lineage, it can promote the proliferation and maturation of megakaryocytic and erythroid progenitors. |
| Document | Type | Information Source | |
|---|---|---|---|
| ACCOFIL Solution for injection / infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| FULPHILA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| GRANOCYTE Powder and solvent for solution for injection/infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| IMREPLYS Powder for solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LONQUEX Solution for injection in pre-filled syringe | MPI, EU: SmPC | European Medicines Agency (EU) | |
| NEULASTIM Solution for injection | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| NEUPOGEN Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| NIVESTYM Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| NYVEPRIA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| PELMEG Solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| RATIOGRASTIM Solution for injection or infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ROLVEDON Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| RYZNEUTA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| RYZNEUTA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| STIMUFEND Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| UDENYCA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ZARZIO Solution for injection / infusion | MPI, EU: SmPC | European Medicines Agency (EU) |